ABOUT

Disease Education Pitch Concepts.

Unbranded campaign for HCPs and patients to boldly change perception of the unmet needs in complement driven renal disease (CDRDs) and PNH. Objective is to create a lasting mindset change that empowers HCPs to extend dialysis free life and for patients to speak up about the impact of the disease and treatments on their everyday life...

Novartis is forging new ground in nephrology. Iptacopan will be a first-to-market, oral, Factor B inhibitor of the alternative pathway. It is an oral treatment currently in development across a number of rare kidney and hematologic diseases.

Iptacopan is poised to become the 1st oral Factor B inhibitor of the alternative pathway in complement diseases.